Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT01552681
• Date of registration: 09/03/2012
• Prospective Registration: Yes
• Primary sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Public title: Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
• Scientific title: A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, for the Treatment of Primary Sjögren's Syndrome (ASJ02)
• Date of first enrolment: July 2012
• Target sample size: 52
• Recruitment status: Terminated
• URL: https://clinicaltrials.gov/show/NCT01552681
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
• Phase: Phase 2

Countries of recruitment

United States

Contacts

• Name: E. William St. Clair, MD
• Affiliation: Duke University

• Name: Judith A. James, MD
• Affiliation: Oklahoma Medical Research Foundation

Key inclusion & exclusion criteria

Inclusion Criteria:

- Has provided written informed consent;

- Between the ages of 18-75 years (inclusive);

- Body weight = 40 kg;

- Meets the revised European criteria proposed by the American-European Consensus Group
for primary Sjögren's Syndrome at screening. These criteria include 3 of the following
4 items:

- ocular symptoms;

- oral symptoms;

- Schirmer's I test showing less than 6 mm of wetting per five minutes in at least
one eye, or filamentary keratitis on slit lamp examination, or positive lissamine
green staining; or

- diminished salivary production (unstimulated whole salivary flow rate = 1.5 mL/15
min); PLUS, either:

- a positive test for serum SS-A and/or SS-B antibodies, or

- focal lymphocytic sialadenitis, with a focus score = 1.0 per 4 millimeters
^2(mm^2) on minor salivary biopsy.

- Stimulated salivary flow of = 0.1 mL/minute (min) (at screening);

- Has one or more of the following systemic manifestations of Sjögren's Syndrome that
are not life-threatening:

- fatigue (as measured by > 50 mm on a 100 mm VAS);

- joint pain (as measured by > 50 mm on a 100 mm VAS);

- peripheral neuropathy (documented by nerve conduction velocity study);

- interstitial lung disease (documented by radiography and/or altered pulmonary
function tests;

- leukocytoclastic vasculitis;

- renal tubular acidosis;

- interstitial nephritis;

- severe parotid swelling;

- other extraglandular manifestations causing organ system dysfunction.

- If taking prednisone (or equivalent corticosteroid), the dose must be = 10 mg/day and
stable for at least 4 weeks prior to Screening;

- If taking hydroxychloroquine, the dose must be stable for at least 12 weeks prior to
Screening;

- If taking a cholinergic stimulant (e.g. pilocarpine, cevimeline), the dose must be
stable for at least 4 weeks prior to Screening;

- Subjects must agree not to become pregnant or to impregnate a female. Because of the
risk involved, participants and their partners (if of reproductive potential) must use
two methods of birth control. They must continue to use both methods until 6 months
after stopping study drug. Two of the birth control methods listed below may be
chosen:

- Hormonal contraception;

- Male or female condoms with or without spermicide;

- Diaphragm or cervical cap with a spermicide;

- Intrauterine device (IUD).

Exclusion Criteria:

- Has an active infection excluding superficial cutaneous fungal or viral infections;

- Has a chronic or persistent infection that might be worsened by immunosuppressive
treatment (e.g., human immunodeficiency virus [HIV], hepatitis B, hepatitis C, or
tuberculosis);

- History of TB or positive intradermal skin test for purified protein derivative (PPD);
positive Mantoux test defined as 10 mm of induration (size of raised bump, not
redness), or equivalent positive TB test result, as per country clinical standards,
during the screening period. Subjects whose PPD induration is = 5 mm but < 10 mm are
eligible for the study if they had a negative chest x-ray during the screening period.
There must be no other clinical evidence of TB on physical examination of the subject.
Note: Subjects who have had prior adequate prophylaxis treatment for latent TB with an
appropriate course of isoniazid or equivalent, per country standards, are not excluded
from study participation. PPD should not be administered within 6 weeks of a
live-virus vaccine;

- History of recurrent significant infections or occurrence of a serious local infection
(e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within
twelve weeks prior to Day 0;

- Receipt of live vaccine within six weeks prior to Day 0;

- History or presence of primary or secondary immunodeficiency;

- History of any life-threatening allergic reactions;

- Is a pregnant or nursing female;

- Ongoing anticoagulant therapy, which is a contraindication for labial salivary biopsy
or tonsil biopsy;

- Concurrent use of anticholinergic agents, such as tricyclic antidepressants,
antihistamines, phenothiazines, antiparkinsonian drugs, anti-asthmatic medications, or
gastrointestinal (GI) medications that cause xerostomia in more than 10% of patients;

- Treatment with any of the following within the defined period prior to Screening:

- 2 years for rituximab;

- 24 weeks for cyclophosphamide;

- 8 weeks for azathioprine, cyclosporine, methotrexate, or mycophenolate mofetil;

- 4 weeks for intravenous immunoglobulin;

- 4 weeks for etanercept;

- 8 weeks for adalimumab;

- 12 weeks for infliximab.

- Prednisone (or equivalent corticosteroid) > 10 mg/day;

- A definite diagnosis of RA, SLE, systemic sclerosis, or dermatomyositis;

- A history of alcohol or substance abuse within 12 months of the screening visit;

- A history of head and neck radiation therapy, sarcoidosis, or graft-versus-host
disease;

- A history of malignancy, except for a resected basal or major squamous cell carcinoma,
cervical dysplasia, or in situ cervical cancer Grade I, within the last five years;

- Severe pulmonary disease as manifested by one of the following at Screening:

- Resting oxygen saturation < 92%;

- Force vital capacity (FVC) < 50% predicted;

- Diffusion lung capacity for carbon monoxide (DLCO) < 50%;

- Abnormal laboratory results for the following parameters at the screening visit:

- Absolute neutrophil count (ANC): < 1,500/mm^3;

- Platelets: < 100,000/mm^3;

- Hemoglobin: < 9 grams (g)/deciliter (dL);

- Serum creatinine: = 2.0 mg/dL;

- AST: > 1.5x upper limit of normal, or

- ALT: > 1.5x upper limit of normal.

- A psychiatric disorder rendering the subject incapable of providing informed consent;

- Plans for foreign travel to countries other than Canada or Western Europe within the
treatment period;

- Inability or unwillingness to follow the protocol;

- Any condition or treatment that, in the opinion of the investigator, places the



Age minimum: 18 Years
Age maximum: 75 Years
Gender: All

Health Condition(s) or Problem(s) studied

Primary Sjögren's Syndrome

Intervention(s)

Biological: Baminercept

Other: Placebo

Primary Outcome(s)

Change From Screening in Stimulated Whole Salivary Flow at Week 24 [Time Frame: Screening to Week 24]

Secondary Outcome(s)

Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 24 [Time Frame: Baseline to Week 24]

Change From Baseline in Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 24 [Time Frame: Week 24]

Change From Baseline in Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 48 [Time Frame: Week 48]

Change From Baseline in the Short Form 36 (SF-36) Physical and Mental Health Component Summary Scores (PCS and MCS) at Week 24 [Time Frame: Week 24]

Change From Baseline in Tear Secretion as Measured by Lissamine Green Staining at Week 24 [Time Frame: Week 24]

Change From Baseline in Visual Analog Scale (VAS) Scores for Sjogren's Syndrome Symptom Survey at Week 24 [Time Frame: Week 24]

Percent of Participants With Injection Site Reaction or Any Grade 2 or Higher Adverse Event Within 24 Hours of Injection [Time Frame: From the time of administration of the first dose of study drug until the participant completed study participation, an average of 48 weeks.]

Change From Screening in Unstimulated Whole Salivary Flow at Week 24 [Time Frame: Screening to Week 24]

Percent of Subjects Classified as Responders According to the Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 24 [Time Frame: Week 24]

Change From Baseline in Patient and Physician Global Assessments of Disease Activity at Week 24 [Time Frame: Week 24]

Change From Baseline in Tear Secretion as Measured by Lissamine Green Staining at Week 48 [Time Frame: Week 48]

Change From Baseline in Tear Secretion as Measured by Schirmer's I Test at Week 24 [Time Frame: Week 24]

Change From Baseline in Visual Analog Scale (VAS) Scores for Sjogren's Syndrome Symptom Survey at Week 48 [Time Frame: Week 48]

Change From Baseline in Tear Secretion as Measured by Schirmer's I Test at Week 48 [Time Frame: Week 48]

Change From Screening in Unstimulated Whole Salivary Flow at Week 48 [Time Frame: Screening to Week 48]

Change From Baseline in Patient and Physician Global Assessments of Disease Activity at Week 48 [Time Frame: Week 48]

Change From Baseline in the Short Form 36 (SF-36) Physical and Mental Health Component Summary Scores (PCS and MCS) at Week 48 [Time Frame: Week 48]

Percent of Participants With Adverse Events of Grade 3 or Higher [Time Frame: From the time of administration of the first dose of study drug until the participant completed study participation, an average of 48 weeks.]

Percent of Subjects Classified as Responders According to the Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 48 [Time Frame: Week 48]

Change From Screening in Stimulated Whole Salivary Flow at Week 48 [Time Frame: Screening to Week 48]

Percent of Participants With Grade 3 or Higher Infection Adverse Event [Time Frame: From the time of administration of the first dose of study drug until the participant completed study participation, an average of 48 weeks.]

Secondary ID(s)

DAIT ASJ02

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Biogen

Autoimmunity Centers of Excellence

Results

• Results available: Yes
• Date Posted: 23/03/2016
• URL: https://clinicaltrials.gov/ct2/show/results/NCT01552681